Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.

Gupta M, Neavin D, Liu D, Biernacka J, Hall-Flavin D, Bobo WV, Frye MA, Skime M, Jenkins GD, Batzler A, Kalari K, Matson W, Bhasin SS, Zhu H, Mushiroda T, Nakamura Y, Kubo M, Wang L, Kaddurah-Daouk R, Weinshilboum RM.

Mol Psychiatry. 2016 Dec;21(12):1717-1725. doi: 10.1038/mp.2016.6. Epub 2016 Feb 23.

2.

Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics.

Abo R, Hebbring S, Ji Y, Zhu H, Zeng ZB, Batzler A, Jenkins GD, Biernacka J, Snyder K, Drews M, Fiehn O, Fridley B, Schaid D, Kamatani N, Nakamura Y, Kubo M, Mushiroda T, Kaddurah-Daouk R, Mrazek DA, Weinshilboum RM.

Pharmacogenet Genomics. 2012 Apr;22(4):247-53. doi: 10.1097/FPC.0b013e32835001c9.

3.

Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.

Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, Snyder K, Drews M, Fiehn O, Zeng Z, Schaid D, Mrazek DA, Kaddurah-Daouk R, Weinshilboum RM.

Clin Pharmacol Ther. 2011 Jan;89(1):97-104. doi: 10.1038/clpt.2010.250. Epub 2010 Nov 24.

4.

Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.

Ji Y, Schaid DJ, Desta Z, Kubo M, Batzler AJ, Snyder K, Mushiroda T, Kamatani N, Ogburn E, Hall-Flavin D, Flockhart D, Nakamura Y, Mrazek DA, Weinshilboum RM.

Br J Clin Pharmacol. 2014 Aug;78(2):373-83. doi: 10.1111/bcp.12348.

5.

Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics.

Ji Y, Biernacka JM, Hebbring S, Chai Y, Jenkins GD, Batzler A, Snyder KA, Drews MS, Desta Z, Flockhart D, Mushiroda T, Kubo M, Nakamura Y, Kamatani N, Schaid D, Weinshilboum RM, Mrazek DA.

Pharmacogenomics J. 2013 Oct;13(5):456-63. doi: 10.1038/tpj.2012.32. Epub 2012 Aug 21.

6.

Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response.

Ji Y, Biernacka J, Snyder K, Drews M, Pelleymounter LL, Colby C, Wang L, Mrazek DA, Weinshilboum RM.

Pharmacogenomics J. 2012 Feb;12(1):78-85. doi: 10.1038/tpj.2010.69. Epub 2010 Sep 28.

7.

Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication.

Athreya AP, Neavin D, Carrillo-Roa T, Skime M, Biernacka J, Frye MA, Rush AJ, Wang L, Binder EB, Iyer RK, Weinshilboum RM, Bobo WV.

Clin Pharmacol Ther. 2019 Oct;106(4):855-865. doi: 10.1002/cpt.1482. Epub 2019 Jun 29.

PMID:
31012492
8.

Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life.

Seripa D, Pilotto A, Paroni G, Fontana A, D'Onofrio G, Gravina C, Urbano M, Cascavilla L, Paris F, Panza F, Padovani A, Pilotto A.

J Psychopharmacol. 2015 May;29(5):623-33. doi: 10.1177/0269881115578159. Epub 2015 Mar 31.

PMID:
25827644
9.

Female sexual dysfunction in patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitor (SSRI) and its association with serotonin 2A-1438 G/A single nucleotide polymorphisms.

Masiran R, Sidi H, Mohamed Z, Mohd Nazree NE, Nik Jaafar NR, Midin M, Das S, Mohamed Saini S.

J Sex Med. 2014 Apr;11(4):1047-1055. doi: 10.1111/jsm.12452. Epub 2014 Feb 18.

PMID:
24533444
10.

Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder.

Illi A, Setälä-Soikkeli E, Kampman O, Viikki M, Nuolivirta T, Poutanen O, Huhtala H, Mononen N, Lehtimäki T, Leinonen E.

Psychiatry Res. 2010 Mar 30;176(1):85-7. doi: 10.1016/j.psychres.2009.03.010. Epub 2010 Jan 13.

PMID:
20071037
12.

Systems Approach to Identify Common Genes and Pathways Associated with Response to Selective Serotonin Reuptake Inhibitors and Major Depression Risk.

Srivastava A, Singh P, Gupta H, Kaur H, Kanojia N, Guin D, Sood M, Chadda RK, Yadav J, Vohora D, Saso L, Kukreti R.

Int J Mol Sci. 2019 Apr 23;20(8). pii: E1993. doi: 10.3390/ijms20081993.

13.

Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.

Li QS, Tian C, Seabrook GR, Drevets WC, Narayan VA.

Transl Psychiatry. 2016 Sep 13;6(9):e889. doi: 10.1038/tp.2016.171.

14.

FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.

Ellsworth KA, Moon I, Eckloff BW, Fridley BL, Jenkins GD, Batzler A, Biernacka JM, Abo R, Brisbin A, Ji Y, Hebbring S, Wieben ED, Mrazek DA, Weinshilboum RM, Wang L.

Pharmacogenet Genomics. 2013 Mar;23(3):156-66. doi: 10.1097/FPC.0b013e32835dc133.

15.

Klotho Gene and Selective Serotonin Reuptake Inhibitors: Response to Treatment in Late-Life Major Depressive Disorder.

Paroni G, Seripa D, Fontana A, D'Onofrio G, Gravina C, Urbano M, Addante F, Lozupone M, Copetti M, Pilotto A, Greco A, Panza F.

Mol Neurobiol. 2017 Mar;54(2):1340-1351. doi: 10.1007/s12035-016-9711-y. Epub 2016 Feb 3.

PMID:
26843110
16.

Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.

Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH.

Ann Pharmacother. 2011 Apr;45(4):441-51. doi: 10.1345/aph.1P482. Epub 2011 Mar 17.

PMID:
21415162
17.

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.

Biernacka JM, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmöller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Baune BT, Kato M, Liu YL, Praphanphoj V, Stingl JC, Tsai SJ, Kubo M, Klein TE, Weinshilboum R.

Transl Psychiatry. 2015 Apr 21;5:e553. doi: 10.1038/tp.2015.47. Erratum in: Transl Psychiatry. 2016 Nov 1;6(11):e937.

18.

Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D.

Adkins DE, Clark SL, Åberg K, Hettema JM, Bukszár J, McClay JL, Souza RP, van den Oord EJ.

Transl Psychiatry. 2012 Jul 3;2:e129. doi: 10.1038/tp.2012.57.

19.

Elevated brain serotonin turnover in patients with depression: effect of genotype and therapy.

Barton DA, Esler MD, Dawood T, Lambert EA, Haikerwal D, Brenchley C, Socratous F, Hastings J, Guo L, Wiesner G, Kaye DM, Bayles R, Schlaich MP, Lambert GW.

Arch Gen Psychiatry. 2008 Jan;65(1):38-46. doi: 10.1001/archgenpsychiatry.2007.11.

PMID:
18180427
20.

Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics.

Liu D, Ray B, Neavin DR, Zhang J, Athreya AP, Biernacka JM, Bobo WV, Hall-Flavin DK, Skime MK, Zhu H, Jenkins GD, Batzler A, Kalari KR, Boakye-Agyeman F, Matson WR, Bhasin SS, Mushiroda T, Nakamura Y, Kubo M, Iyer RK, Wang L, Frye MA, Kaddurah-Daouk R, Weinshilboum RM.

Transl Psychiatry. 2018 Jan 10;8(1):10. doi: 10.1038/s41398-017-0056-8.

Supplemental Content

Support Center